iRadimed Corporation $IRMD Stock Acquired by Bridge City Capital LLC

Key Points

• Bridge City Capital increased its iRadimed stake by 36.5% in the third quarter to 96,975 shares, while institutional investors collectively own 92.34% of the company.
• iRadimed reported third-quarter revenue of $24.2 million, up 14% year over year and above expectations, with non-GAAP EPS of $0.55 meeting consensus estimates.
• Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in MRidium 3870 pump output; analysts maintain a “Moderate Buy” consensus with a $120 target price.

Bridge City Capital LLC lifted its holdings in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 36.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,975 shares of the medical equipment provider's stock after purchasing an additional 25,932 shares during the period. iRadimed comprises approximately 1.7% of Bridge City Capital LLC's holdings, making the stock its 14th biggest holding. Bridge City Capital LLC owned 0.76% of iRadimed worth $8,361,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of iRadimed in the second quarter worth $92,485,000. Dimensional Fund Advisors LP raised its stake in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider's stock worth $21,768,000 after purchasing an additional 9,017 shares in the last quarter. Ranger Investment Management L.P. acquired a new position in shares of iRadimed during the second quarter worth $9,398,000. Bank of New York Mellon Corp bought a new stake in shares of iRadimed during the 2nd quarter valued at about $7,252,000. Finally, Sei Investments Co. grew its holdings in iRadimed by 17.2% during the first quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider's stock worth $7,153,000 after buying an additional 10,908 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Record revenue and year-over-year growth: Third-quarter revenue reached $24.2 million, up 14% from the prior-year period and 18% sequentially. Revenue also exceeded the FactSet consensus estimate of $23.5 million. iRadimed Third Quarter 2026 Financial Results
• Positive Sentiment: Improved profitability: GAAP diluted EPS was $0.51, while non-GAAP diluted EPS was $0.55, up from $0.41 and $0.47, respectively, in the second quarter. Non-GAAP EPS matched analysts’ consensus estimate, while the company maintained a 26.7% net margin and 23.45% return on equity. IRadimed Q3 Earnings and Outlook
• Positive Sentiment: Potential production acceleration: Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in output for its MRidium 3870 infusion pump, supporting a potential path toward a $100 million annual revenue run rate. iRadimed Q4 Revenue Outlook

Insider Activity

In related news, Director Monty K. Allen sold 1,419 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the sale, the director directly owned 19,581 shares of the company's stock, valued at $1,691,994.21. This trade represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 34.60% of the company's stock.

iRadimed Stock Performance

Shares of NASDAQ:IRMD opened at $76.68 on Monday. The stock has a fifty day moving average of $85.66 and a 200-day moving average of $92.69. The company has a market capitalization of $980.51 million, a PE ratio of 41.01 and a beta of 0.91. iRadimed Corporation has a one year low of $76.35 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $23.47 million. iRadimed had a return on equity of 24.40% and a net margin of 26.85%. As a group, research analysts forecast that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Investors of record on Friday, November 13th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, November 13th. This represents a $0.80 annualized dividend and a yield of 1.0%. iRadimed's dividend payout ratio is presently 42.78%.

Analysts Set New Price Targets

Several analysts have issued reports on IRMD shares. Needham & Company LLC started coverage on shares of iRadimed in a research report on Tuesday, September 22nd. They set a "hold" rating for the company. Weiss Ratings upgraded shares of iRadimed from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 16th. Finally, Wall Street Zen cut iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $120.00.

About iRadimed

iRadimed Corporation NASDAQ: IRMD develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.